Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

v3.4.0.3
Net Loss Per Share
 3 Months Ended
Mar. 31, 2016
Earnings Per Share [Abstract]  
Net Loss Per Share
13. Net Loss Per Share
 
Refer to Note 15, Subsequent Event, for a discussion of the Company’s May 4, 2016 reverse stock split.
 
The following table sets forth the computation of basic and diluted net loss per share:
 
 
 
Three months ended March 31,
 
 
 
2016
 
2015
 
Numerator:
 
 
 
 
 
 
 
Net loss applicable to common stockholders, basic and diluted
 
$
(6,775)
 
$
(4,115)
 
 
 
 
 
 
 
 
 
Denominator
 
 
 
 
 
 
 
Weighted-average number of shares, basic and diluted
 
 
15,388
 
 
14,542
 
 
 
 
 
 
 
 
 
Net loss per share, basic and diluted
 
$
(0.44)
 
$
(0.28)
 
 
Recognition of previously deferred revenue and cost of goods in the quarter ended March 31, 2016 as described in Note 2. Summary of Significant Accounting Policies and Estimates, Medical Device Revenue and Cost of Revenue Recognition reduced net loss applicable to common stockholders by $2,358, or $0.15 per share.
 
The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:
 
 
 
March 31,
 
 
 
2016
 
2015
 
Options to purchase common stock
 
 
1,979
 
 
1,496
 
Warrants for common stock
 
 
4,085
 
 
1,966
 
Common stock issuable upon conversion of preferred shares
 
 
1,309
 
 
-
 
Total common stock equivalents
 
 
7,373
 
 
3,462